Literature DB >> 645720

Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition.

W L Henry, A W Nienhuis, M Wiener, D R Miller, V C Canale, S Piomelli.   

Abstract

The heart was evaluated by echocardiography in 56 patients at risk for myocardial iron deposition. Fifty-four had congenital anemia for which they required repeated transfusions, and two had primary hemochromatosis. The data, plotted according to one of three functions of the body surface area, were compared to values obtained in 105 normal subjects whose age spanned a similar range. Left ventricular wall thickness, transverse dimension and mass, as well as left atrial transverse dimension, were increased in the majority of patients with chronic iron overload despite the infrequent occurrence of cardiac enlargement on routine chest films (32 per cent) or electrocardiographic abnormality (16 per cent). Left ventricular ejection fraction was normal in all but four patients. These four patients died within a six month follow-up period suggesting that deterioration in systolic function is an indicator of poor prognosis. Our findings indicate that echocardiography provides a simple noninvasive means for assessing changes in cardiac structure and function that should prove useful in the serial evaluation of patients who are at risk for the development of myocardial iron deposition.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 645720     DOI: 10.1016/0002-9343(78)90572-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  The effect of iron overload in the hearts of patients with beta-thalassemia.

Authors:  S V Brili; A I Tzonou; S S Castelanos; C J Aggeli; C A Tentolouris; C E Pitsavos; P K Toutouzas
Journal:  Clin Cardiol       Date:  1997-06       Impact factor: 2.882

2.  Iron overload and heart fibrosis in mice deficient for both beta2-microglobulin and Rag1.

Authors:  M M Santos; M de Sousa; L H Rademakers; H Clevers; J J Marx; M W Schilham
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy.

Authors:  T Germans; R Nijveldt; W P Brouwer; J G J Groothuis; A M Beek; M J W Götte; A C van Rossum
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

4.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

Review 5.  Thalassemic cardiopathy: current concepts.

Authors:  J C Mohan; K S Reddy
Journal:  Indian J Pediatr       Date:  1984 Jul-Aug       Impact factor: 1.967

6.  Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration.

Authors:  Se Na Moon; Ji Whan Han; Hui Seung Hwang; Mee Jeong Kim; Soon Ju Lee; Jae Young Lee; Chang Kyu Oh; Dae Chul Jeong
Journal:  Pediatr Cardiol       Date:  2011-06-09       Impact factor: 1.655

7.  Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study.

Authors:  T Lombardo; C Tamburino; G Bartoloni; M L Morrone; V Frontini; F Italia; S Cordaro; A Privitera; V Calvi
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

Review 8.  Iron overload cardiomyopathies: new insights into an old disease.

Authors:  P Liu; N Olivieri
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

9.  Left ventricular function in beta thalassaemia major.

Authors:  K C Lau; A M Li; P W Hui; C Y Yeung
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

10.  Effect of iron overload on exercise capacity in thalassemic patients with heart failure.

Authors:  Sophie Mavrogeni; Efstathios Gotsis; Dimitrios Verganelakis; Eleni Berdousis; Athanasios Dritsas; Genovefa Kolovou; Panagiotis Toulas; Vassilios Ladis
Journal:  Int J Cardiovasc Imaging       Date:  2009-08-13       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.